Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 4/20 | 0.34 |
| ▸ | CTSA | P10619 | 5/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914700 | 1.00 | PAICS (0.34) | PAICSCTSAROCK2ROCK1UTS2R | |
| SCHEMBL2492517 | 0.94 | PAICS (0.36) | PAICSCTSAROCK2ROCK1HSP90AB1 | |
| SCHEMBL2492514 | 0.94 | PAICS (0.36) | PAICSCTSAROCK2ROCK1HSP90AB1 | |
| SCHEMBL913398 | 0.94 | PAICS (0.34) | PAICSROCK2ROCK1UTS2RHSP90AB1 | |
| SCHEMBL913397 | 0.94 | PAICS (0.34) | PAICSROCK2ROCK1UTS2RHSP90AB1 | |
| SCHEMBL914649 | 0.92 | PAICS (0.35) | PAICSCTSAROCK2ROCK1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL912179 | 0.92 | PAICS (0.35) | PAICSCTSAROCK2ROCK1HSP90AB1 | |
| SCHEMBL914405 | 0.90 | CTSA (0.35) | PAICSCTSAUTS2RHSP90AB1ATM | |
| SCHEMBL914407 | 0.90 | CTSA (0.35) | PAICSCTSAUTS2RHSP90AB1ATM | |
| SCHEMBL914403 | 0.90 | CTSA (0.35) | PAICSCTSAUTS2RHSP90AB1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653276-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2014-02-18 | — | — | US | claimed |
| US-20130252974-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI (FR) | 2013-09-26 | — | — | US | claimed |
| EP-2238110-B1 | 5.6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS ANTAGONISTS FOR UROTENSINE II RECEPTORS | SANOFI SA (FR) | 2011-10-26 | — | — | EP | claimed |
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-8653276-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130252974-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI (FR) | 2013-09-26 | — | — | US | disclosed |
| US-8466292-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009426-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | PAICS 146/4885CTSA 421/4885ROCK2 2218/4885 |
| US-20130252974-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | PAICS 146/4885CTSA 421/4885ROCK2 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.